Gout disease treatment market
Gout Disease Treatment Market, by Drug Class (Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Corticosteroids, Colchicine, Urate-lowering Agents, and Monoclonal Antibody), by Route of Administration (Oral and Injectable), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027
- Nov 2019
- CMI3082
- 182 Pages
- Excel & Pdf
- Pharmaceutical
Gout is the condition that is characterized by formation of excess of uric acid in body tissues that results in the formation of crystals of monosodium urate. Symptoms of gout includes intense pain, swelling, and stiffness in the joints. The progression stages of gout includes asymptomatic hyperuricemia (gout), acute gout, interval or intercritical gout, chronic tophaceous gout, and pseudogout. Anti-gout drugs are available in oral and injectable dosage form. Orally administered drugs such as nonsteroidal anti-inflammatory drugs, corticosteroids, and colchicine are equally effective in the treatment of acute gout. Most of the major brands such as Zurampic, Duzallo, Zyloprim, Celebrex, and Voltaren are available in oral dosage form in the market. Thus, availability of such orally administered drugs is expected to drive growth of global gout disease treatment market over the forecast period.
The global gout disease treatment market was valued at US$ 2,385.7 million in 2018, and is expected to exhibit a CAGR of 6.7% during the forecast period (2019–2027).
Figure 1. Global Gout Disease Treatment Market Share (%), By Drug Class
Source: Coherent Market Insights Analysis (2019)
Increasing research and development activities, in order to develop novel treatment approach for gout disease and regulatory approval for the anti-gout drugs are expected to be a major factor driving growth of the global gout disease treatment market over the forecast period
Increasing pipeline studies to develop novel anti-gout drugs is expected to drive the global gout disease treatment market growth over the forecast period. For instance, Arthrosi Therapeutics, will initiate phase 2 clinical trial study in December 2019 to evaluate the pharmacodynamics and pharmacokinetic profile, safety, and tolerability of AR882 (drug candidate) alone or in combination with febuxostat or allopurinol, when administered to gout patients. The study is estimated to be completed by June 2020.
Moreover, increasing product approvals by regulatory authority is expected to drive growth of the gout disease treatment market. For instance, in December 2018, SunGen Pharma, a privately held company, received the U.S. FDA approval for Prednisone (generic version of Deltasone), a drug with various strengths 10 mg, 20 mg, and 50 mg tablets to treat various conditions such as arthritis, gout, blood disorders, immune system disorders, and others.
Penetration of generic version of anti-gout drugs is expected to provide growth opportunities to market players, in order to increase their share in gout disease treatment market.
Adverse effects and risks associated with drugs such as NSAIDs and urate-lowering agents is expected to hamper the global gout disease treatment market growth
Most of the gout drugs are associated with severe side effects, which is expected to decrease demand for these drugs. Nonsteroidal anti-inflammatory drugs (NSAIDs) may cause some gastric problems such as indigestion. In few cases, these drugs can cause gastric ulcers, bleeding, and rashes in gastrointestinal (GI) tract. Moreover, side effects such as intolerability and contraindication is expected to limit the usage of these drugs in treatment of gout. For instance, in February 2019, the U.S. Food and Drug Administration (FDA) has added a new boxed warning for febuxostat, due to increased risk of death associated with Uloric (febuxostat) compared to other gout medicine, allopurinol. Febuxostat belongs to the urate-lowering agents.
Global Gout Disease Treatment Market- Regional Analysis
Based on region, the global gout disease treatment market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
Among regions, North America is expected to hold a dominant position in the market, owing to presence of major players and non-profit organizations in the region. These market players and non-profit organizations are focused on launching new programs and awareness campaigns to educate people about gout disease and help healthcare practitioners in the treatment of gout disease. For instance, in May 2016, Takeda Pharmaceuticals U.S.A., Inc. and Arthritis Foundation launched a program, Let’s Speak Gout, based on new joint research to enhance disease management in patients with gouty arthritis.
Moreover, Europe gout disease treatment market is expected to exhibit significant growth over the forecast period, owing to increasing regulatory approval of the products indicated for the treatment of gout disease. For instance, in August 2018, Grünenthal GmbH received marketing authorization from European Union for its product Duzallo (Allopurinol and Lesinurad), a fixed-dose combination (FDC) therapy indicated for the treatment of hyperuricaemia in adult gout patients. The marketing authorization was granted for 28 European Union member states and European Economic Area (EEA) countries, Norway, Iceland, and Liechtenstein.
Figure 2: Global Gout Disease Treatment Market Share (%), By Region
Source: Coherent Market Insights Analysis (2019)
Global Gout Disease Treatment Market - Competitive Landscape
Key players operating in the global gout disease treatment market include AstraZeneca Plc, Takeda Pharmaceutical Company Limited, Novartis International AG, Teijin Pharma Limited, Simcere Pharmaceutical, JW Pharmaceutical Corporation, Horizon Therapeutics Plc., Hikma Pharmaceuticals Plc, Ironwood Pharmaceuticals, Inc., CymaBay Therapeutics, Inc., and Zyla Life Sciences (Pty) Ltd.,
Table of Contents
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Mergers and Acquisitions
- Regulatory Scenario
- Reimbursement Scenario
- PEST Analysis
- Epidemiology
- Global Gout Disease Treatment Market, By Drug Class, 2016 – 2027, (US$ Million)
- Introduction
- Market Share Analysis, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Corticosteroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Colchicine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million) Corticosteroids
- Urate-lowering Agents
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Monoclonal Antibody
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Global Gout Disease Treatment Market, By Route of Administration, 2016 – 2027, (US$ Million)
- Introduction
- Market Share Analysis, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Global Gout Disease Treatment Market, By Distribution Channel, 2016 – 2027, (US$ Million)
- Introduction
- Market Share Analysis, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Global Gout Disease Treatment Market, By Region, 2016 – 2027, (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, By Region, 2017 – 2027
- Regional Trends
- North America
- Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
- U.S.
- Canada
- Europe
- Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
- China
- Japan
- India
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Africa
- Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Country/Region, 2016 – 2027, (US$ Million)
- North Africa
- Central Africa
- South Africa
- Middle East
- Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
- GCC
- Israel
- Rest of Middle East
- Competitive Landscape
- Heat Map Analysis
- Company Profiles
- AstraZeneca Plc
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Takeda Pharmaceutical Company Limited
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Novartis International AG
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Teijin Pharma Limited
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Simcere Pharmaceutical
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- JW Pharmaceutical Corporation
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Horizon Therapeutics plc
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Hikma Pharmaceuticals Plc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Ironwood Pharmaceuticals, Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Zyla Life Sciences.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- CymaBay Therapeutics, Inc..
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Analyst Views
- Section
- References
- Research Methodology
- About us and Sales Contact
*Browse 32 market data tables and 35 figures on "Gout Disease Treatment Market” - Global forecast to 2027”.